Clinical Study
Headache Associated with Myasthenia Gravis: The Impact of Mild Ocular Symptoms
Table 1
Demographic and clinical features of patients with MG-associated headache.
| | MG-associated headache (+) () | MG-associated headache (−) () | value |
| | Female gender | 22 (88%) | 102 (64%) |
*0.03 | | Mean age, y (range) | 49.4 ± 17.2 | 57.0 ± 16.8 | n.s. | | Mean disease duration, y (range) | 9.2 ± 7.6 | 8.2 ± 8.2 | n.s. | | AChR-Ab positive | 16 (64%) | 118 (74%) | n.s. | | Thymoma present | 2 (8%) | 37 (23%) | n.s. | | Thymectomy | 9 (36%) | 74 (47%) | n.s. | | PSL administration | 15 (60%) | 84 (53%) | n.s. | | CNI administration | 8 (32%) | 43 (27%) | n.s. | | QMG scores | | | | | Total | 8.4 ± 4.9 | 6.2 ± 4.6 | n.s. | | Ocular symptoms | 2.2 ± 1.6 | 1.6 ± 1.8 | n.s. | | Bulbar symptoms | 0.3 ± 0.5 | 0.2 ± 0.6 | n.s. | | Limb symptoms | 4.9 ± 3.0 | 3.7 ± 2.8 | n.s. | | Trunk symptoms | 1.1 ± 0.7 | 0.8 ± 0.8 | n.s. |
|
|
-value < 0.05.
MG: myasthenia gravis; QMG: quantitative myasthenia gravis scoring; n.s.: not significant; AChR-Ab, autoantibodies to the acetylcholine receptor; PSL: prednisolone; CNI: calcineurin inhibitor.
|
